eCardiacRehab - a Hybrid Patient-Centered eHealth Programme
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: eCardiacRehab.
- Who it may be relevant to
- Registry conditions: Comorbidities and Coexisting Conditions, Ethics, Continuity of Patient Care, Older Adults (65 Years and Older). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Norway
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
eCardiacRehab - a Randomized Controlled Trial on a Hybrid Home-Based Patient-Centered eHealth Programme With Tailored Solutions
Overview
The overall aim of eCardiacRehab trial is to meet rehabilitation needs of patients with coronary artery disease (CAD) regardless of their access to traditional place-based rehabilitation by developing and evaluating the efficacy and cost effectiveness of an interdisciplinary and comprehensive home-based hybrid programme. eCardiacRehab address patient- and system level challenges to increase access to cardiac rehabilitation (CR). We give particular attention to older patients, women, and those with comorbidities or mental health challenges. The vision of the hybrid home-based eCardiacRehab programme is to make CR available to all. eCardiacRehab is a prospective, multicentre randomized open-label blinded end point evaluation (PROBE) trial. The primary endpoint is a hierarchical composite endpoint using a win-ratio framework combining cardiovascular (CV) death, unplanned contacts to the Emergency Department (ED) for observation or admission (\>24 hours) for CV disease, and quality of life. Inclusion criteria are adult Scandinavian speaking patients (≥ 18 years) who have a Norwegian national identification number, with CAD treated with Percutaneous Coronary Intervention (PCI), are living at home, and have internet available to them and providing signed informed consent. Exclusion criteria are patients with severe aortic stenosis, severe arrhythmias, expected lifetime less than one year as determined by study personnel, otherwise clinically unstable, not fully revascularized, awaits PCI or coronary artery bypass graft operation (CABG) or inability to comply with the study protocol due to any physical disability, somatic disease, cognitive impairment or mental health challenges as determined by study personnel.
Detailed description
The primary objective is to test whether a hybrid CR programme (the eCardiacRehab) reduces the risk of CV death and CV related ED contacts, and improves quality of life compared to usual care in patients with CAD treated with PCI.
The secondary and exploratory objectives (planned for the main study) are:
* To assess whether eCardiacRehab improves each of the components of the primary endpoint separately compared to usual care. * To assess clinical outcomes associated with eCardiacRehab in the following subgroups: age, sex (men vs. women), hypertension (yes vs. no), multimorbidity (yes vs. no), mental health challenges (yes vs. no). * To study whether eCardiacRehab reduces the total number of ED contacts compared to usual care. * To study whether eCardiacRehab reduces the risk of all-cause death compared to usual care. * To assess whether eCardiacRehab improves long-term medication adherence to cardiometabolic medications (e.g. antiplatelets, lipid lowering drugs, antihypertensive, and antidiabetics) in patients after PCI utilizing data from the Norwegian Prescribed Drug Registry, and by patients' self-report. * To assess whether participation in eCardiacRehab improves the total number of CV risk factors. * To assess whether participation in eCardiacRehab is non-inferior to conventional, in-person CR among the subset of usual care participants who attend standard place-based CR.
Other secondary objectives (for eCardiacRehab sub-studies) are:
* To conduct a cost-utility study, from a societal and healthcare system perspective perspective; cost per QALY. Cost categories include i) the intervention; ii) inpatient/outpatient visits; iii) community-based healthcare; iv) medications; v) patient-borne costs and vi) production loss due to sick leave. Further, to estimate cost-effectiveness acceptability curves to estimate the probability that the intervention is cost-effective at different willingness to pay for a unit of the outcome measure. * To study whether eCardiacRehab affects the following patient-reported outcomes: quality of life, angina, anxiety, depression, sleep status, health literacy and eHealth literacy, frailty status, fatigue, continuity of care, and adherence to healthy lifestyle recommendations (physical activity, tobacco use, sleep, diet). * To study whether eCardiacRehab improves objectively measured cardiorespiratory fitness (VO2peak), intensity minutes (activity tracker) and self-reported physical activity and exercise. * To study whether eCardiacRehab improves body composition (visceral fat, muscle mass, body fat, BMI). * To study whether eCardiacRehab improves change in number of controlled risk factors. * To study whether eCardiacRehab improves low-density lipoproteins.
Exploratory objectives (for substudies):
* To evaluate whether eCardiacRehab improves long-term medication adherence to cardiometabolic medications (e.g. antiplatelets, lipid lowering drugs, antihypertensive, and antidiabetics) in patients after PCI utilizing data from therapeutic drug monitoring (assessed by direct methods quantifying drug concentrations in blood). * To study differences in blood and urine biomarker concentrations between patients in the intervention and usual care group. * To study changes in blood pressure associated with digital cardiac rehabilitation. * To study cardiovascular mortality up to 10 years after index hospitalization. * To study cardiovascular ED contact up to 10 years after index hospitalization. * To study all-cause mortality up to 10 years after index hospitalization. * To study all-cause ED contact up to 10 years after index hospitalization. * To study the total number of ED contacts up to 10 years after index hospitalization.
Primary and secondary endpoints will be obtained by collection of self-reported data, clinical examination including blood and urine sample collection, and linkage to the following national registries: The Norwegian Registry of Invasive Cardiology, the Norwegian Population Registry, the Cause of Death Registry, the Norwegian Patient Registry, the Norwegian Myocardial Infarction Register, the Norwegian Prescription Database, the Norwegian Labour and Welfare Administration, Statistics Norway, the FD-Trygd database (social security micro data for research), the Control and payment of reimbursements to health service providers (KUHR) database and local hospital registries.
Interventions
- Other eCardiacRehab
12-week digital cardiac rehabilitation
Primary outcome measures
- Composite clinical hierarchy of outcomes [Time frame: Death and hospitalization 1 year after study inclusion. Quality of life after 3 months.]
Secondary outcome measures (12)
- Cardiovascular mortality [Time frame: 1, 3, 5 years]
- Cardiovascular Emergency Department contact [Time frame: 1, 3, 5 years]
- All-cause mortality [Time frame: 1, 3, 5 years]
- All-cause Emergency Department contact [Time frame: 1, 3, 5 years]
- The Myocardial Infarction Dimensional Assessment Scale (MIDAS) [Time frame: Pre-intervention, immediately after the intervention, 6-month follow-up, 12-month follow-up, 24-month follow-up, 36-month follow-up.]
- The Seattle Angina Questionnaire (SAQ- 7) [Time frame: Baseline, Pre-intervention, Immediately after the intervention, 6-month follow-up, and 12-month follow-up.]
- RAND-12 [Time frame: Baseline, Pre-intervention, Immediately after the intervention, 6-month follow-up, 12-month follow-up, 24-month follow-up, 36-month follow-up.]
- WHOQOL-BREF [Time frame: Baseline, Pre-intervention, Immediately after the intervention, 6-month follow-up, 12-month follow-up, 24-month follow-up, 36-month follow-up.]
- The my experience of taking medicines (MYMEDS) questionnaire [Time frame: Baseline, Pre-intervention, Immediately after the intervention, 6-month follow-up, 12-month follow-up, 24-month follow-up, 36-month follow-up.]
- Therapeutic drug monitoring [Time frame: Maximum 1 year]
- EQ-5D-5L [Time frame: Baseline, Pre-intervention, Immediately after the intervention, 6-month follow-up, 12-month follow-up, 24-month follow-up, 36-month follow-up.]
- Smoking status [Time frame: Baseline, Pre-intervention, Immediately after the intervention, 6-month follow-up, 12-month follow-up, 24-month follow-up, 36-month follow-up.]
Eligibility criteria
Inclusion criteria
- Adult Norwegian (or Scandinavian) speaking patients (≥ 18 years) who have a Norwegian national identification number
- With coronary artery disease after percutaneous coronary intervention
- Living at home
- Have internet available
- Provide signed informed consent
Exclusion criteria
- Patients with cognitive impairment that may interfere with the ability to comply with the study protocol
- Severe aortic stenosis
- Severe arrhythmias
- Expected lifetime less than one year as determined by study personnel
- Otherwise clinically unstable
- Not fully revascularized
- Awaits percutaneous coronary intervention or coronary artery bypass graft surgery
- Inability to comply with the study protocol due to any physical disability, somatic disease, or mental problems as determined by study personnel
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Norway · 1 center
- Haukeland University Hospital — Bergen
Publications
- Pettersen TR, Schjott J, Allore H, Bendz B, Borregaard B, Fridlund B, Hadjistavropoulos HD, Larsen AI, Nordrehaug JE, Rasmussen TB, Rotevatn S, Valaker I, Wentzel-Larsen T, Norekval TM; CONCARD Investigators. Discharge Information About Adverse Drug Reactions Indicates Lower Self-Reported Adverse Drug Reactions and Fewer Concerns in Patients After Percutaneous Coronary Intervention. Heart Lung Cir PMID 38238118
- Norekval TM, Bale M, Bedane HK, Hole T, Ingul CB, Munkhaugen J. Cardiac rehabilitation participation within 6 months of discharge in 37 136 myocardial infarction survivors: a nationwide registry study. Eur J Prev Cardiol. 2024 Nov 18;31(16):1977-1980. doi: 10.1093/eurjpc/zwad350. No abstract available. PMID 37943676
Identifiers
NCT: NCT07590635 · F-12624